We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alkeus Pharmaceuticals, Inc., a private, late-stage biopharmaceutical company, announced that the U.S. FDA granted Breakthrough Therapy Designation to ALK-001 for the treatment of Stargardt Disease.